Cethromycin HCl accumulates preferentially in the liver, where dormant malaria parasites reside.
Its pharmacologic profile supports:
Cethromycin HCl inhibits parasite protein synthesis through apicoplast targeting — a biologically validated pathway relevant to liver-stage malaria.
Cethromycin free base has been administered to more than 5,000 human subjects in prior clinical development, establishing a substantial human exposure and safety database. This human exposure supports early clinical development and helps de-risk initial clinical evaluation.
Cethromycin HCl is supported by composition-of-matter and formulation intellectual property protecting the hydrochloride salt and associated solid forms. These patents strengthen AliquantumRx’s ability to advance differentiated clinical development and support long-term commercial exclusivity. Additional patent filings and development-stage protections continue to be pursued to support lifecycle management.